Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)’. The study aims to demonstrate the superiority of maridebart cafraglutide over a placebo in reducing body weight among adults with type 2 diabetes who are either overweight or obese, highlighting its potential significance in addressing a prevalent health issue.
The intervention being tested is maridebart cafraglutide, a drug administered subcutaneously in varying doses (high, medium, and low) over a period of 72 weeks. The primary purpose of this intervention is to evaluate its effectiveness in weight reduction compared to a placebo.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. Both participants and investigators are blinded to the treatment allocations, ensuring unbiased results. The primary focus of the study is treatment efficacy.
The study began on March 17, 2025, with its primary completion estimated for a future date. The last update was submitted on July 24, 2025. These dates are crucial as they mark the progress and timeline for potential data availability and subsequent analysis.
This study update could have significant implications for Amgen’s stock performance and investor sentiment, as successful results may enhance the company’s position in the diabetes treatment market. Competitors in the pharmaceutical industry are closely watching developments in weight management solutions for diabetes, which could influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.